Therapeutic use of serotoninergic hallucinogens: a review of the evidence and of the biological and psychological mechanisms

Publication date: Available online 3 December 2019Source: Neuroscience & Biobehavioral ReviewsAuthor(s): Rafael Guimarães dos Santos, Jaime Eduardo Cecilio HallakAbstractSerotoninergic hallucinogens include drugs such as lysergic acid diethylamide (LSD), dimethyltryptamine (DMT) and psilocybin. Recent trials with single/few doses of these compounds show that they induce rapid and sustained antidepressive, anxiolytic, and antiaddictive effects. These effects are also observed in religious groups using the DMT-containing brew ayahuasca. The agonist action of these substances on 5-HT2A receptors expressed in frontal and limbic areas increase glutamatergic transmission and neuroplasticity. These neurochemical effects are associated with acute alterations on self-perception and increases in introspection and positive mood, and with subacute and long-term decreases in psychiatric symptoms, increases in some personality traits such as openness, improvements in emotional processing, and increases in empathy. These are preliminary but promising results that should be further explored in controlled trials with larger sample sizes, especially considering that these compounds could be beneficial in the treatment of treatment-resistant psychiatric disorders.
Source: Neuroscience and Biobehavioral Reviews - Category: Neuroscience Source Type: research